Titlebook: Cancer Drug Resistance; Methods and Protocol Marta Baiocchi Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive lice

巡洋

書目名稱Cancer Drug Resistance影響因子(影響力)




書目名稱Cancer Drug Resistance影響因子(影響力)學(xué)科排名




書目名稱Cancer Drug Resistance網(wǎng)絡(luò)公開度




書目名稱Cancer Drug Resistance網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cancer Drug Resistance被引頻次




書目名稱Cancer Drug Resistance被引頻次學(xué)科排名




書目名稱Cancer Drug Resistance年度引用




書目名稱Cancer Drug Resistance年度引用學(xué)科排名




書目名稱Cancer Drug Resistance讀者反饋




書目名稱Cancer Drug Resistance讀者反饋學(xué)科排名

BRIEF

Patient-Derived Breast Cancer Tissue Cultures for Anti-Endocrine Drug Assays,t cancers express the estrogen receptor alpha (ER), which plays a pivotal role in the pathobiology of the disease and are therefore classified as ER-positive (ER.). In fact, targeting of the ER signaling pathway is the main therapeutic strategy for ER. breast cancer. Despite the success of endocrine

Immobilize

誤傳

詞匯記憶方法

雪上輕舟飛過

雪上輕舟飛過

A Label Retaining System to Capture Slow-Cycling Cancer Cells, adjuvant therapy. Slow-cycling cancer cells (SCCC) represent a cellular status rather than a cell population present in a minor proportion, even in growing tumors. We have adapted the pulse-chase expression of histone H2B fused to enhanced GFP (H2BeGFP) for labelling and isolating SCCC. SCCC show c

Awning

A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance,e manner. Of the various circulating biomarkers available for liquid biopsy, circulating tumor cells (CTC)?and circulating tumor DNA (ctDNA)?are the most intensively studied to date. However, CTC and ctDNA represent different tumor components, therefore, complementary information from both sources m

Derogate

Assessment of Tumor Heterogeneity in High-Grade Serous Ovarian Cancer: Mass Cytometry to Understandmotherapy; however, despite recent development of new therapeutic approaches based on combination of chemotherapy and innovative targeted-therapies, most of them relapse due to chemoresistance. Many studies have been carried out to decipher the high heterogeneity of ovarian cancer cells that drives

Melanoma